KRAS and familial pancreatic carcinoma: Hyperactivating mutations in KRAS are found in 86–96% of pancreatic cancers, 40–54% of colorectal cancers (CRCs), and 27–39% of lung adenocarcinoma4,5 and its mutations show a high degree of association with cancer progression and poor prognosis, prompting efforts to understand its role in tumorigenesis and identify drugs targeting KRAS6–8.